Data-driven stock analysis, valuation deep dives, and financial forensics. Every article backed by the numbers.
Shares hit a fresh 52-week low this week. At 1.3 times trailing sales and a 3.8 percent dividend yield, Nike trades at the lowest multiple since the LeBron James era of Cleveland championships. The franchise has a problem. The price now compensates for it.
A 200-plane Beijing commitment lifted the narrative, not the financials. Free cash flow has been negative in three of the last five years, capex has tripled since 2021, and the math still doesn't work at $240 per share.
At 14x forward earnings, a 3.8% yield, and 16 straight quarters of $5 billion in capital returns, Chevron is offering a margin of safety the market keeps refusing to credit.
FY25 capex hit $64.6 billion, up 45% year over year. Operating income hit $128.5 billion, up 17%. The capital efficiency on AI infrastructure spend is the bull case.
At a $44 billion market cap and a 3.3% net margin, the Cash App growth narrative is doing all the work. Strip out the narrative and the numbers are not what bulls want them to be.
GS just printed a 14.5% revenue growth quarter, the highest in three years. The composition is the issue, not the headline. Trading is doing the work that capital markets cannot.
Boeing reappeared on the Dow leadership list this week alongside Apple and Nvidia. The technical picture is real, but the fundamental case underneath it is more complicated than the chart implies.
A $5.2 trillion market cap with revenue still compounding above 70% year over year is a profile the public market has never seen at this scale. The signals are telling a specific story.
Uber's commitment to 50,000 autonomous R2 SUVs reframes Rivian as a fleet platform, not a consumer EV maker. The signal is what kind of business the market is being asked to value.
Visa trades at 24.5x forward, Mastercard at 25.3x. Both have just made aggressive stablecoin moves. The numbers tell you which is positioned better.
Cloudflare trades at 169x forward, Datadog at 93x. Both grew revenue 30%+ this quarter. Only one is generating the cash flow profile that justifies the premium.
Pfizer trades at 8.7x forward earnings and a 6.6% dividend yield. The market is telling you something. Here are five reasons it is not a screaming buy.
Snowflake's Horizon Catalog repositioning is being treated as a feature update. The five datapoints below say it is more important than that.
Lilly's revenue compounded 56% in the most recent quarter on a $30+ billion run-rate. The GLP-1 cycle is the most consequential pharmaceutical event since the statin era. The data behind the thesis.
JPMorgan delivered $59 billion in net income in 2025, a 17% return on tangible common equity, and bought back roughly $25 billion in stock. The capital allocation framework is the bull case.